Tightened regulations for Rx/reimbursement adult incontinence products had a negative impact on volume sales in 2021. Furthermore, due to COVID-19 restrictions, patients who would normally have been diagnosed with incontinence were reluctant to visit a doctor.
With the focus on quality healthcare, incontinence sufferers, especially those in care facilities for the elderly and disabled, need special care. This means that they need value-added products which can offer both the carer and incontinence sufferer convenience.
A trend seen in retail adult incontinence was also seen in Rx/reimbursement incontinence, with manufacturers pushing towards incontinence pants rather than pads, because of the comfort they offer. Unlike in retail adult incontinence, often consumers cannot make a personal choice about which brand they choose, as products depend on the health insurance and the pharmacist that the user goes to.
The decline in volume sales of Rx/reimbursement adult incontinence products is expected to continue over the forecast period, as the Dutch healthcare system aims to contain spiralling costs. Instead, the focus will remain on quality healthcare for those most in need.
Manufacturers are already working with carers and users of incontinence products to produce more tailored products that offer convenience and make the work of the carer lighter. Sensors which can measure when the material is wet can reduce the burden of changing the product at predetermined times.
The push by manufacturers to switch to disposable incontinence pants is likely to continue over the forecast period, as pants command a higher unit price than standard pads. As a result, a great deal of product development is expected in the category, as seen with the development of sensors.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Rx/Reimbursement adult incontinence industry in Netherlands with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Rx/Reimbursement adult incontinence industry in Netherlands, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
To qualify for reimbursement, typically a note from a physician is required (a “prescription”) indicating that the patient is in need of incontinence supplies. Depending on the local system in place, supplies are then either shipped directly to consumer home by a designated service or a consumer has to pick up products at a pharmacy. Please be advised that services and routes to consumers can vary even within the same country and vary by state/region. Some countries provide reimbursement through income tax deductions. If this is the case in your market, we EXCLUDE this type of reimbursement from our Rx/Reimbursement coverage as it would be impossible to track. Additionally, consumers would have already purchased the products in retail before claiming tax deductions, and as such the products have already been counted as retail sales. The same logic applies to institutional sales. If a nursing home purchased adult incontinence products from a distributor/manufacturer for distribution to its patients/residents, these products would be included as AFH adult incontinence in our coverage, even though sometimes patients might claim healthcare deductions for costs of stay at a nursing home.See All of Our Definitions
This report originates from Passport, our Rx/Reimbursement adult incontinence research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!